GlassScriptPhysician profile
Sabrina Helen Hellbusch
NPI 1629577515
$6,984.82
in general payments reported to CMS, 2019-2025
33 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $967 · 2022: $1,453 · 2023: $1,373 · 2024: $1,484 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,490 · Education: $75.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,489.98 |
| Education | $75.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,617.68 | 2021-2025 | |
| Lundbeck LLC | $1,404.85 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $584.34 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $559.12 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $471.32 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $318.29 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Tris Pharma INC | $267.88 | 2021-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $210.01 | 2021-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $195.33 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $177.28 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $129.42 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $116.66 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $115.34 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $89.68 | 2022-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $75.69 | 2022-2023 | Nuplazid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $73.60 | 2022-2024 | Azstarys |
| Biogen, INC. | $72.01 | 2024-2025 | Zurzuvae |
| Jazz Pharmaceuticals INC. | $63.55 | 2021-2022 | |
| Noven Therapeutics, LLC | $61.42 | 2024-2025 | Xelstrym, Secuado |
| Itamar Medical INC | $48.60 | 2024 | Watchpatone |
| Vanda Pharmaceuticals INC. | $41.47 | 2021-2022 | |
| Bausch Health US, LLC | $41.00 | 2022 | |
| Neos Therapeutics, LP | $34.05 | 2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Collegium Pharmaceutical, INC. | $33.54 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $30.00 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $29.51 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $28.75 | 2022-2023 | Quviviq |
| Indivior INC. | $20.68 | 2024 | Perseris |
| Azurity Pharmaceuticals, INC. | $19.53 | 2024 | Horizant |
| Adlon Therapeutics L.P. | $14.75 | 2021 | |
| Merck Sharp & Dohme LLC | $14.57 | 2021 | |
| Harmony Biosciences LLC | $12.66 | 2022 | |
| Alfasigma USA, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Hellbusch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.